Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02928289 · ClinicalTrials.gov registry record · NA

Safety and Effectiveness of the Sight Sciences VISCO™360 Versus SLT in Primary Open Angle Glaucoma

A NA study, sponsored by Sight Sciences.

Terminated
Registry status
NA
Development phase
29
Enrollment target

NCT02928289 is a NA study that was terminated before completion, run by Sight Sciences. The registered enrollment target is 29 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02928289, a NA study, was terminated before completion, sponsored by Sight Sciences.

TERMINATED
Registry status
NA
Development phase
29 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the safety and effectiveness of the Sight Sciences VISCO™360 Viscosurgical System in reducing intraocular pressure (IOP) in adult, pseudophakic subjects with open-angle glaucoma.

Interventions

  • DEVICE VISCO360 ab interno canaloplasty surgery
  • DEVICE Selective Laser Trabeculoplasty (SLT)

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2017-01-23
Est. Completion 2019-01-17
Phase NA

Sponsor

Sight Sciences

14 total trials

What the Registry Record Tells You About NCT02928289

The ClinicalTrials.gov registry entry for NCT02928289 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sight Sciences, which has 14 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which VISCO360 ab interno canaloplasty surgery is the first listed.

NCT02928289 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02928289 about?

NCT02928289 is a clinical study titled "Safety and Effectiveness of the Sight Sciences VISCO™360 Versus SLT in Primary Open Angle Glaucoma". The purpose of this study is to evaluate the safety and effectiveness of the Sight Sciences VISCO™360 Viscosurgical System in reducing intraocular pressure (IOP) in adult, pseudophakic subjects with open-angle glaucoma.

What is the current status of trial NCT02928289?

This trial is currently terminated. It is a NA study. The enrollment target is 29 participants. The study started on 2017-01-23. Estimated completion is 2019-01-17.

What interventions are being tested in trial NCT02928289?

The interventions under investigation include: VISCO360 ab interno canaloplasty surgery (DEVICE), Selective Laser Trabeculoplasty (SLT) (DEVICE).

Who is sponsoring clinical trial NCT02928289?

This trial is sponsored by Sight Sciences, which has 14 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.